{
    "xml": "<topic id=\"PHP5096\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/propiverine-hydrochloride\" basename=\"propiverine-hydrochloride\" title=\"PROPIVERINE HYDROCHLORIDE\">\n<title>PROPIVERINE HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_868\" namespace=\"/interactions/list-of-drug-interactions/antimuscarinics/propiverine\">Propiverine</xref>\n</p>\n<data name=\"vtmid\">421592007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_567112641\" title=\"Antimuscarinics\">Antimuscarinics</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34659\" title=\"ANTIMUSCARINICS (SYSTEMIC)\" namespace=\"/drug-classes/antimuscarinics-systemic\">ANTIMUSCARINICS (SYSTEMIC)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP44397\" outputclass=\"indicationsAndDose\" rev=\"1.38\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Urinary frequency, urgency and incontinence associated with overactive bladder</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8239;mg 1&#8211;2 times a day, increased if necessary up to 15&#8239;mg 3 times a day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By mouth using modified-release capsules</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>30&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Urinary frequency, urgency and incontinence associated with neurogenic bladder instability</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using immediate-release medicines</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8239;mg 3 times a day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44365\" outputclass=\"pregnancy\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid (restriction of skeletal development in <i>animals</i>).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44523\" outputclass=\"breastFeeding\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44417\" outputclass=\"hepaticImpairment\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in moderate to severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP44337\" outputclass=\"renalImpairment\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Max. daily dose 30&#8239;mg if eGFR less than 30&#8239;mL/minute/1.73m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in mild or moderate impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59541\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.8\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5096-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/propiverine-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77027\" title=\"Tablet\" namespace=\"/drugs/propiverine-hydrochloride/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77033\" title=\"Modified-release capsule\" namespace=\"/drugs/propiverine-hydrochloride/modified-release-capsule\">Modified-release capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78573\" namespace=\"/treatment-summaries/urinary-frequency-enuresis-and-incontinence\" title=\"Urinary frequency, enuresis and incontinence\" count=\"1\" rel=\"backlink\">Urinary frequency, enuresis and incontinence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_868\" namespace=\"/interactions/list-of-drug-interactions/antimuscarinics/propiverine\" title=\"Propiverine\" count=\"1\" rel=\"link\">Propiverine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34659\" namespace=\"/drug-classes/antimuscarinics-systemic\" title=\"ANTIMUSCARINICS (SYSTEMIC)\" count=\"1\" rel=\"link\">ANTIMUSCARINICS (SYSTEMIC)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77027\" namespace=\"/drugs/propiverine-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77033\" namespace=\"/drugs/propiverine-hydrochloride/modified-release-capsule\" title=\"Modified-release capsule\" count=\"1\" rel=\"link\">Modified-release capsule</xref>\n</links>\n</topic>",
    "id": "PHP5096",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/propiverine-hydrochloride",
    "basename": "propiverine-hydrochloride",
    "title": "PROPIVERINE HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_868",
            "label": "Propiverine"
        }
    ],
    "vtmid": "421592007",
    "drugClassification": [
        "Antimuscarinics"
    ],
    "inheritsFromClass": [
        "ANTIMUSCARINICS (SYSTEMIC)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Urinary frequency, urgency and incontinence associated with overactive bladder",
                        "html": "Urinary frequency, urgency and incontinence associated with overactive bladder"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using modified-release capsules"
                    ],
                    "textContent": "By mouth using modified-release capsules",
                    "html": "By mouth using modified-release capsules"
                },
                "adult": [
                    {
                        "textContent": "15 mg 1&#8211;2 times a day, increased if necessary up to 15 mg 3 times a day.",
                        "html": "<p>15&#8239;mg 1&#8211;2 times a day, increased if necessary up to 15&#8239;mg 3 times a day.</p>"
                    },
                    {
                        "textContent": "30 mg once daily.",
                        "html": "<p>30&#8239;mg once daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Urinary frequency, urgency and incontinence associated with neurogenic bladder instability",
                        "html": "Urinary frequency, urgency and incontinence associated with neurogenic bladder instability"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using immediate-release medicines"
                    ],
                    "textContent": "By mouth using immediate-release medicines",
                    "html": "By mouth using immediate-release medicines"
                },
                "adult": [
                    {
                        "textContent": "15 mg 3 times a day.",
                        "html": "<p>15&#8239;mg 3 times a day.</p>"
                    }
                ]
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid (restriction of skeletal development in animals).",
                "html": "<p>Manufacturer advises avoid (restriction of skeletal development in <i>animals</i>).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;present in milk in animal studies.",
                "html": "<p>Manufacturer advises avoid&#8212;present in milk in <i>animal </i>studies.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in moderate to severe impairment.",
                "html": "<p>Avoid in moderate to severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Max. daily dose 30 mg if eGFR less than 30 mL/minute/1.73m2.",
                "html": "<p>Max. daily dose 30&#8239;mg if eGFR less than 30&#8239;mL/minute/1.73m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in mild or moderate impairment.",
                "html": "<p>Manufacturer advises caution in mild or moderate impairment.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.",
                "html": "<p>The need for continuing therapy for urinary incontinence should be reviewed every 4&#8211;6 weeks until symptoms stabilise, and then every 6&#8211;12 months.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77027",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77033",
                "label": "Modified-release capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78573",
                "label": "Urinary frequency, enuresis and incontinence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_868",
                "label": "Propiverine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34659",
                "label": "ANTIMUSCARINICS (SYSTEMIC)",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77027",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77033",
                "label": "Modified-release capsule",
                "type": "medicinalForm"
            }
        ]
    }
}